Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis
Dorota Kujawa,
Lukasz Laczmanski,
Slawomir Budrewicz,
Anna Pokryszko-Dragan,
Maria Podbielska
Affiliations
Dorota Kujawa
Laboratory of Genomics & Bioinformatics, Ludwik Hirszfeld Institute of Immunology & Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland
Lukasz Laczmanski
Laboratory of Genomics & Bioinformatics, Ludwik Hirszfeld Institute of Immunology & Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland
Slawomir Budrewicz
Department of Neurology, Wroclaw Medical University, Wroclaw, Poland
Anna Pokryszko-Dragan
Department of Neurology, Wroclaw Medical University, Wroclaw, Poland
Maria Podbielska
Laboratory of Microbiome Immunobiology, Ludwik Hirszfeld Institute of Immunology & Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland
ABSTRACTMultiple sclerosis (MS) causes long-lasting, multifocal damage to the central nervous system. The complex background of MS is associated with autoimmune inflammation and neurodegeneration processes, and is potentially affected by many contributing factors, including altered composition and function of the gut microbiota. In this review, current experimental and clinical evidence is presented for the characteristics of gut dysbiosis found in MS, as well as for its relevant links with the course of the disease and the dysregulated immune response and metabolic pathways involved in MS pathology. Furthermore, therapeutic implications of these investigations are discussed, with a range of pharmacological, dietary and other interventions targeted at the gut microbiome and thus intended to have beneficial effects on the course of MS.